Knee Osteoarthritis - Pipeline Insight, 2025

This “Knee Osteoarthritis - Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Knee Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Knee Osteoarthritis: Understanding

Knee Osteoarthritis: Overview

Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases it also causes reduced function and disability; some people are no longer able to do daily tasks or work. The knee joint connects the thighbone (femur), shinbone (tibia), calf bone (fibula), and kneecap (patella) with each other. The ends of the bones and the inside of the kneecap are covered with cartilage. Healthy cartilage has a smooth gliding surface that allows low-friction movement. Osteoarthritis develops if the cartilage softens and becomes cracked and thinner. Cartilage can’t repair itself as well as other types of tissue can, so any major damage is lasting.

Osteoarthritis of the knee can develop in three areas:

On the inside of the knee joint (medial)

On the outside of the knee joint (lateral)

Osteoarthritis of the knee typically starts with knee pain that only occurs when a person put pressure on the joint. If the osteoarthritis gets worse over time, this pain gets stronger and more frequent. A person may even feel it when the person rest the joint or at night, and it may keep from sleeping. Person might have other symptoms too, like joint stiffness. Some people’s joints are especially painful in the evenings or mornings. Depending on the part of the knee that is affected, the inner or outer side of the knee may hurt more. If the area under the kneecap is affected, the pain may be most noticeable when getting up and climbing stairs. Under the kneecap (patellofemoral). To diagnose osteoarthritis of the knee, the doctor will ask about symptoms like constant or recurrent pain and temporary knee stiffness. They will check the range of motion of the knee joint, look at leg alignment, and check for other possible causes of the pain, like meniscus or ligament damage. A knee X-ray is usually enough to diagnose osteoarthritis. Special examinations, like an X-ray of the whole leg, computed tomography (CT), or magnetic resonance imaging (MRI) are usually not needed. There are various treatment options for osteoarthritis of the knee: Which ones are worth considering depends on things like how advanced it is, whether person have any other medical conditions, and what the person expect from the treatment. There are also many treatment options for osteoarthritis of the knee like Topical anti-inflammatory painkillers to be applied to the affected joint, like a gel containing diclofenac, can relieve osteoarthritis pain in some people, and are an easy-to-use treatment option with few side effects.

'Knee Osteoarthritis - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Knee Osteoarthritis pipeline landscape is provided which includes the disease overview and Knee Osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Knee Osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Knee Osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Knee Osteoarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Knee Osteoarthritis.

Knee Osteoarthritis Emerging Drugs Chapters

This segment of the Knee Osteoarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Knee Osteoarthritis Emerging Drugs

Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug. Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, slowing of cartilage breakdown, and generation of cartilage. Currently, the drug is in Phase III stage of its development for the treatment of Knee Osteoarthritis.

• EP-104IAR: Eupraxia Pharmaceuticals Inc

EP-104IAR, is designed to meet the significant unmet medical need and market demand for long-lasting disease relief in multiple indications benefitting from highly localized and longer delivery of corticosteroids. The lead indication is for pain relief in knee OA. With EP-104IAR, Eupraxia hopes to change the way knee OA pain is treated. Currently approved corticosteroids are very effective at reducing pain for a short duration late in the disease but can expose the body to unwanted local and systemic side effects. EP-104IAR is designed to prolong the duration of pain relief with fewer unwanted side effects. It encapsulates a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane, part of Eupraxia's patented technology platform. Injected into the knee, EP-104IAR is designed to diffuse the corticosteroid slowly into the knee joint providing local therapeutic concentrations for up to six months. This has the potential dual advantage of providing longer duration of pain relief with fewer systemic side effects. A robust safety and tolerability profile would also benefit the estimated 70% of knee OA patients that experience pain in both knees by allowing simultaneous treatment of both affected joints. Currently, the drug is in Phase II stage of its development for the treatment of Knee Osteoarthritis.

LG00034053: LG Chem

LG34053 is an injectable new drug with a new mechanism of blocking the inflammatory pathway and inhibiting chondrocyte apoptosis. LG Chem expects that the new drug will be different from existing symptomatic pain relief drugs. LG00034053 is the world's first injection-type new drug that blocks inflammatory pathways and inhibits cartilage cell death. Preclinical results showed that the pain relief effect lasted for several months with just one administration, and it also improved effects on cartilage damage, the root cause of arthritis. It has showed the possibility of developing a new drug that is different from existing pain relief symptomatic drugs. Currently, the drug is in Phase I/II stage of its development for the treatment of Knee Osteoarthritis.

Knee Osteoarthritis: Therapeutic Assessment

This segment of the report provides insights about the different Knee Osteoarthritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Knee Osteoarthritis

• There are approx. 50+ key companies which are developing the therapies for Knee Osteoarthritis. The companies which have their Knee Osteoarthritis drug candidates in the most advanced stage, i.e. phase III include, Biosplice Therapeutics

Phases

The report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Knee Osteoarthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Knee Osteoarthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Knee Osteoarthritis drugs.

Knee Osteoarthritis Report Insights

• Knee Osteoarthritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Knee Osteoarthritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Knee Osteoarthritis drugs?
• How many Knee Osteoarthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Knee Osteoarthritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Knee Osteoarthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Knee Osteoarthritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biosplice Therapeutics
• Eupraxia Pharmaceuticals Inc
• LG Chem
• BioSenic
• Techfields Pharma
• BioTissue,Inc
• OliPass Corporation
• Peptinov
• Novartis
• UnicoCell Biomed
• Gwo Xi Stem Cell Applied Technology
• Novartis
• Centrexion Therapeutics
• Akan Biosciences
• Anika Therapeutics
• Taiwan Liposomal Company

Key Products

• Lorecivivint
• EP-104IAR
• LG00034053
• JTA-004
• X 0002
• TTAX03
• OLP 1002
• PPV 06
• Canakinumab
• Elixcyte
• GXCPC1
• LNA043
• CNTX-4975-05
• Autologous adipose derived stromal vascular fraction therapeutic
• Cingal
• TLC599

This product will be delivered within 1-3 business days.